Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This is a study to see if a medicine called belantamab mafodotin is safe and helpful for people with a type of cancer called multiple myeloma. These people have already had another kind of treatment called CAR-T therapy. They will start taking belantamab mafodotin about two to four months after CAR-T therapy. They will take the new medicine every 56 days for a few cycles. They will get belantamab mafodotin through a needle in their vein.
This is a study to see if a medicine called belantamab mafodotin is safe and helpful for people with a type of cancer called multiple myeloma. These people have already had another kind of treatment called CAR-T therapy. They will start taking belantamab mafodotin about two to four months after CAR-T therapy. They will take the new medicine every 56 days for a few cycles. They will get belantamab mafodotin through a needle in their vein.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a multicenter phase II, open-label study evaluating the efficacy and safety of belantamab mafodotin maintenance in participants with relapsed and/or refractory multiple myeloma (RRMM) who have received commercially available anti-BCMA CAR-T-cell therapy. Subjects will be enrolled 60-130 days after chimeric antigen receptor T-cell therapy (CAR-T) and receive belantamab mafodotin as maintenance therapy. Each maintenance cycle will have a duration of 56 days (+/- three days) and belantamab mafodotin will be administered at a dose of 2.5 mg/kg IV on day 1 of each cycle.
This is a multicenter phase II, open-label study evaluating the efficacy and safety of belantamab mafodotin maintenance in participants with relapsed and/or refractory multiple myeloma (RRMM) who have received commercially available anti-BCMA CAR-T-cell therapy. Subjects will be enrolled 60-130 days after chimeric antigen receptor T-cell therapy (CAR-T) and receive belantamab mafodotin as maintenance therapy. Each maintenance cycle will have a duration of 56 days (+/- three days) and belantamab mafodotin will be administered at a dose of 2.5 mg/kg IV on day 1 of each cycle.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: